On July 10, Oklo Inc. rose 5.18% in regular trading, trading at approximately $49.79/share, with turnover of $2.19 billion.

On the news front, Oklo announced that its Groves Isotope Test Reactor located in Texas has received approval of the documented safety analysis from the US Department of Energy. The approval represents the facility's final safety basis and included technical analysis of potential hazards, safety controls, and operating requirements needed to support safe startup. The project has now officially entered the final pre-startup review phase, with remaining steps being readiness review and startup approval. Following startup approval, the facility will be authorized to receive and load nuclear fuel, conduct startup testing, and proceed toward first criticality. Oklo is targeting first criticality for Groves this month.

Groves is the first privately developed advanced nuclear reactor project in the United States to receive a documented safety analysis approval, marking a critical commercialization milestone. Additionally, in June, the DOE approved the preliminary documented safety analysis for Oklo's Aurora powerhouse at Idaho National Laboratory under the Reactor Pilot Program, further reinforcing the company's multi-project regulatory momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)